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D
espite substantial improvements in insulin therapy and the care of patients with type 1 diabetes mellitus, a subgroup of patients is disabled by refractory hypoglycemia. Cell-based therapy with islet transplantation offers the possibility of improved glycemic control. The past three decades have witnessed substantial progress in islet transplantation. 1-3 Before the year 2000, few centers performing islet transplantation achieved high rates of sustainable insulin independence after this procedure among patients with type 1 diabetes mellitus. [1] [2] [3] In 2000, Shapiro et al. 4 reported their initial findings with up to a year of follow-up in seven consecutive subjects treated with glucocorticoid-free immunosuppressive therapy combined with infusion of an adequate mass of freshly prepared islets from two or more pancreases from deceased donors. 5 In all seven subjects, insulin independence was achieved, with tight glycemic control and correction of glycated hemoglobin levels. This treatment became known as the Edmonton protocol. The goal of our study was to explore the feasibility and reproducibility of this protocol for islet preparation and management after transplantation, including immunosuppression.
Me thods

Study Design
The nine international centers -six in North America and three in Europe -that participated in the study used a common protocol (the Edmonton protocol) of islet preparation and post-transplantation care. We required that investigators at each site demonstrate a consistent ability to prepare human islets under Good Manufacturing Practice conditions and apply standardized criteria for islet enumeration and product release. Investigators at each of the participating sites underwent intensive training in the preparation process and used common batch lots of collagenase enzyme. The level of previous experience in clinical islet transplantation varied among the participating centers from substantial to none.
We designed the study to be a single-group, phase 1-2 trial. The study was organized by the Immune Tolerance Network, initiated by the National Institutes of Health, with a goal of establishing centers of excellence to conduct future tolerance-based trials (details are available at www.immunetolerance.org). 6 Our target enrollment was 36 subjects, with 4 subjects per site, on the basis of available funding. Up to three islet infusions were permitted per subject until insulin independence was reached, on condition that partial islet function persisted after the preceding transplantation. The study had a planned follow-up of 3 years for all subjects after their last transplantation.
Study Definitions
We defined insulin independence as freedom from the need to take exogenous insulin, with adequate glycemic control, as defined by a glycated hemoglobin level of less than 6.5%, with a glucose level after an overnight fast not exceeding 140 mg per deciliter (7.8 mmol per liter) more than three times in any week (based on the morning fasting glucose level) and not exceeding 2-hour postprandial levels of 180 mg per deciliter (10 mmol per liter) more than four times per week. We recognize that applying more stringent measures for glycemic control might have altered the outcome.
We defined partial graft function as a C-peptide level of at least 0.3 ng per milliliter and a requirement for insulin or inadequate glycemic control. Complete graft loss was defined as primary nonfunction (an initial C-peptide level of <0.3 ng per milliliter), early graft loss (an initial increase in the C-peptide level but a decrease to less than 0.3 ng per milliliter within 2 months), or withdrawal from further treatment, with cessation of immunosuppression imputed from 13 weeks after withdrawal. A severe hypoglycemic event in the year after the last transplantation was defined as an episode of neuroglycopenia with unawareness severe enough for the subject to require assistance; such episodes were ascertained both by chart review and interviews for each subject.
Study End Points
The primary end point was defined as insulin independence with adequate glycemic control 1 year after the final transplantation. Secondary end points included insulin independence with adequate glycemic control throughout follow-up; improved values for levels of glycated hemoglobin, the mean amplitude of glycemic excursions, and basal and stimulated blood C-peptide levels in response to arginine challenge; and a reduction in the need for insulin, as compared with baseline. Written informed consent was obtained from subjects and from the families of deceased donors. international trial of the edmonton protocol for islet tr ansplantation n engl j med 355;13 www.nejm.org september 28, 2006 Formal approval was obtained from the investigational review board at each site.
Recipient Selection
Eligible subjects were between the ages of 18 and 65 years, had undetectable C-peptide levels, and had had type 1 diabetes mellitus for more than 5 years with recurrent neuroglycopenia, including reduced awareness of their hypoglycemic episodes or severe glycemic lability. To confirm eligibility, an endocrinologist or diabetologist assessed subjects independently of the islet-transplantation team. Appropriate attempts to optimize intensive insulin therapy and glycemic monitoring had failed in all subjects. Major exclusion criteria were noncorrectable coronary artery disease; a bodymass index (the weight in kilograms divided by the square of the height in meters) of more than 26; a weight of more than 70 kg (154 lb) for women or 75 kg (165 lb) for men; an insulin requirement of more than 0.7 U per kilogram of body weight per day; a glycated hemoglobin level of more than 12%; inadequate renal reserve, which was defined as a serum creatinine level of more than 1.5 mg per deciliter (133 μmol per liter), a creatinine clearance of less than 80 ml per minute per 1.73 m 2 of body-surface area, or an albumin level of more than 300 mg per 24-hour period (macroalbuminuria); and negative results on serologic analysis for Epstein-Barr virus at the time of assessment (to avoid reactivation of the virus after transplantation).
Donor Selection
Pancreases were obtained from brain-dead multiorgan donors ranging in age from 15 to 70 years. The organs were transported in chilled University of Wisconsin solution without the use of perfluorodecalin, for a maximum cold-storage time of less than 12 hours. Standard criteria for donor exclusion were applied to minimize the risk of transmission of donor-derived infection or cancer.
Immunosuppressive Regimen
The immunosuppressive regimen was based on that previously described in the Edmonton protocol. 4 Five doses of daclizumab at a dose of 1 mg per kilogram were administered intravenously over a period of 8 weeks after each transplantation. Sirolimus was administered once daily to achieve a target trough therapeutic range of 12 to 15 ng per milliliter for 3 months after transplantation, af- * BMI denotes body-mass index (the weight in kilograms divided by the square of the height in meters), EGL early graft loss, PNF primary nonfunction of the graft, WD withdrawn voluntarily with subsequent complete graft loss, and NA not applicable. † The subject withdrew from the study on the basis of a personal decision. ‡ The subject withdrew from the study because of an immunosuppressive side effect (headache). § The subject withdrew from the study because of immunosuppressive side effects (mouth ulcers, diarrhea). ¶ The subject withdrew from the study because of compliance issues.
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Islet Preparation and transplantation
Islets were prepared locally in Good Manufacturing Practice-grade facilities at each of the nine sites, according to identical standard operating procedures. The pancreas was distended by controlled ductal perfusion with the use of common batch lots of Liberase human islet enzyme (Roche Diagnostics), previously validated at the participating sites. 7 The pancreas was digested in a Ricordi chamber and purified on continuous Ficoll gradients on a cooled apheresis system (model 2991, Cobe Laboratories). The islets were then washed and resuspended in transplant medium (Mediatech), and the manufactured islet-cell product was infused into the portal vein without culture within 2 hours after completion of the isolation and purification. 4, 8, 9 The final criteria for islet product release included an islet infusion compatible with the ABO blood group, an islet mass of 5000 islet equivalents per kilogram or more (on the basis of the weight of the recipient), an islet purity of 30% or more, a membrane-integrity viability of 70% or more, a packed-tissue volume of less than 10 ml, negative Gram's staining, and an endotoxin content of 5 endotoxin units per kilogram or less (on the basis of the weight of the recipient).
A cumulative islet mass of 10,000 islet equivalents per kilogram or more was delivered with at least two islet infusions, unless insulin independence was achieved with a single transplant. A third islet infusion was offered if circulating C peptide was detectable and insulin independence was not achieved after two infusions. The percutaneous transhepatic approach for portal venous access was used in all cases, with Doppler ultrasonography performed on days 1 and 7 after transplantation. 10,11
Statistical Analysis
On the basis of an enrollment of 36 subjects, we set the predicted proportion reaching the primary end point at 70%, with a 95% confidence interval (CI) of 57% to 83%. Event rates are expressed as percentages and the 95% CI is reported for specified outcomes. We used Fisher's exact test to assess the homogeneity of the rate of success according to the research site and the chi-square test to assess the rate of success according to the level of experience at the site. With four subjects per site, there was adequate power (80%, with an alpha of 0.05) to detect extreme differences in proportions (0.01 to 0.99). Continuous measures, presented as means with the standard deviation or 95% CI, were compared by t-test analysis of variance, generalized estimating equations, or nonparametric testing. Kaplan-Meier estimates for outcome measures were made for the overall data and for stratadefined variables and were compared by means of the log-rank chi-square test. All reported P values are two-sided.
R esults
Subjects
We screened approximately 2000 prospective subjects centrally to determine eligibility for enrollment. Of these subjects, only 149 (7%) fulfilled the initial stringent screening criteria and were referred to the sites. All nine sites enrolled subjects (seven sites with four subjects each, one site with five subjects, and one site with three subjects). All 36 subjects had one or more primary diabetesrelated indications for enrollment: 35 (97%) had severe recurrent hypoglycemia, 20 (56%) had severe glycemic lability, and 19 (53%) had progressive secondary complications of type 1 diabetes mellitus (neuropathy, retinopathy, or nephropathy). Table 1 shows the demographic and clinical characteristics of the subjects, including baseline insulin requirements and the duration of disease, the transplanted islet mass, and stimulated C-peptide levels at 1 year.
Number of Transplants and follow-up
Enrollment took place between May 2001 and January 2003, and in all 36 subjects, the primary end point was determined by June 2005. The 36 subjects received a total of 77 islet infusions, with 11 subjects (31%) receiving 1 infusion, 9 (25%) receiving 2 infusions, and 16 (44%) receiving 3 infusions. We evaluated 35 subjects at 2-year follow-up and 21 subjects at 3-year follow-up or later. The median follow-up time was 41 months (range, 37 to 50) from the time of the first transplantation.
Outcomes
One year after the final transplantation, 16 of 36 subjects (44%) had reached the primary end point (5 with one transplant, 6 with two transplants, and 5 with three transplants), 10 subjects (28%) had partial graft function, and 10 subjects (28%) had complete graft loss (4 with primary nonfunction, 2 with early graft loss, and 4 who withdrew from further treatment). All subjects with residual islet function were completely protected from severe hypoglycemic episodes, as reported from days 28 to 365 after transplantation. As of February 2006, 24 of 36 subjects (67%) had at least partial graft function (11 subjects at 3 years), and 6 subjects were insulin-independent (1 subject at 3 years). ( Fig. 1A) . Of the 21 subjects who reached insulin independence (58%), 16 subjects (76%) were dependent on insulin again at 2 years (Fig. 1B) . There was a significant correlation between attainment of insulin independence and autoantibody status (P = 0.03) (Fig. 1C) . C-peptide secretion was detectable (≥0.3 ng per milliliter) in 70% of subjects at 2 years (Fig. 1D ). Subjects were evaluated for a reduction in the need for insulin, levels of fasting glucose and glycated hemoglobin, basal C-peptide secretion, and the mean amplitude of glycemic excursions over time; subjects with insulin independence or partial graft function had a substantial benefit in all measures during 2 years of follow-up, as compared with subjects with complete graft loss ( Fig. 2A  through 2E ). Subjects who reached the primary end point had full protection from severe hypoglycemia or hyperglycemia, and those with partial function had a marked benefit in glycemic control, in contrast to their baseline status (Fig. 2F) . Figure 3A shows site-to-site heterogeneity in the proportion of subjects who reached the primary end point (range, 0 to 100%; P = 0.05 by Fisher's exact test). Experience with islet transplantation at various sites and the use of sirolimus in the 2 years preceding the start of the trial are shown in Figure 3B . A positive relation between previous experience with islet transplantation at a site and the attainment of the primary end point was observed. The primary end point was reached by 12 of 18 subjects (67%) at sites where four or more transplantations had been performed in the preceding 2 years, as compared with only 4 of 18 subjects (22%) at sites where fewer than four transplantations had been performed (P = 0.007 by the chi-square test).
Adverse Events
There were no reports of death, post-transplantation lymphoproliferative disease, cancer, or opportunistic infections among the study subjects. There was no disease related to cytomegalovirus or Epstein-Barr virus on the basis of clinical presentation or central monitoring.
Of a total of 38 serious adverse events, 23 were considered to be related to the study therapy (18 of which were associated with hospitalization). Serious immunosuppression-related events included neutropenia (five cases), pneumonia, mouth ulcers, gastrointestinal conditions (two cases), fever, chest pain, pericardial effusion, pyelonephritis, worsening genital herpes, and appendiceal abscess. Procedure-related events included acute intraperitoneal bleeding in 7 of 77 islet infusions (9%), in 4 cases requiring blood transfusion, and in 1 laparotomy. A second subject required laparotomy for a bile leak, which subsequently resolved. Severe hypoglycemia developed in one subject with primary graft nonfunction immediately after islet infusion. Complete thrombosis of the portal vein did not occur. Partial branch-vein occlusions were identified in 2 of 36 subjects (6%) and were treated successfully with temporary anticoagulation.
The 10 most common nonserious adverse events were mouth ulceration (in 92% of subjects), anemia (81%), leukopenia (75%), diarrhea (64%), head- ache (56%), neutropenia (53%), nausea (50%), vomiting (42%), acne (39%), and fatigue (39%). Nine of 36 subjects (25%) were switched to a nonsirolimus-based alternative immunosuppressive regimen because of side effects: 8 subjects were switched to mycophenolate mofetil, and 1 subject to azathioprine. Mild hepatic steatosis was observed on routine magnetic resonance imaging 2 years after transplantation in 4 of 13 subjects (31%); it was not associated with clinical sequelae. In terms of renal function, a modest decline in creatinine clearance with a mild elevation in serum creatinine levels was observed over time, which was associated in some cases with increased albuminuria (Fig. 4) .
Sensitization
Only five subjects had detectable levels of alloantibody during the study. Two subjects had alloantibodies without donor specificity before their first transplantation, and one of these two had primary nonfunction of the graft. The other reached insulin independence with only a single transplant. One subject had antidonor antibody before receiving the first transplant but nonetheless had partial graft function and eventually became insulin-independent after a third islet infusion. New antidonor antibodies developed in two subjects at 4.5 and 6 months after the loss of islet function and subsequent withdrawal of immunosuppressive therapy.
Discussion
The results of this international, multicenter trial confirm previous experiences with the Edmon- The left-hand bars show the percentage of subjects who reached the primary end point (blue), had partial graft function (yellow), had primary graft nonfunction (red), had early graft loss (brown), or withdrew from the study and had subsequent complete graft loss (gold). The right-hand bars show the percentage of subjects who had insulin independence at any time during the first year after transplantation (gray). In Panel B, the two bars for each site show the number of islet transplantations that were performed (yellow) and the number of cases that were managed with the use of sirolimus (blue) in the 2 years preceding the initiation of the trial.
The New England Journal of Medicine ton protocol at single centers and demonstrate the reproducibility and benefits of islet-alone transplantation in patients who have type 1 diabetes mellitus with unstable glycemic control. 4, 5, 12, 13 The trial succeeded in standardizing pancreas selection, islet processing, product-release criteria, recipient selection, and post-transplantation care under a Food and Drug Administration investigational new drug submission. Investigators reported no deaths, cancer, or post-transplantation lymphoproliferative disease during the observation period. Although procedure-related complications were manageable, side effects related to immunosuppression prompted a change in therapy in 25% of subjects and occasionally precipitated withdrawal of subjects from the study. With the exception of the high frequency of mouth ulceration, anemia, and leukopenia, the frequency of immunosuppression-related side effects was similar to that typically seen in solidorgan transplantation. It was worrisome to observe a decline in renal function in some subjects, presumably reflecting the combined toxic effects of tacrolimus and sirolimus on preexisting diabetic nephropathy, which highlights a need for the development of less toxic immunosuppressive therapy. Acute bleeding from the percutaneous hepatic puncture site is now considered avoidable . In Panel C, the two horizontal lines denote levels of urinary albumin of 30 mg per day and 300 mg per day. At baseline, 2 of 36 subjects (6%) had urinary albumin levels between 30 mg and 300 mg per day (microalbuminuria), and 1 (3%) had urinary albumin levels that exceeded 300 mg per day (macroalbuminuria), which was a deviation from the protocol. The remainder of subjects had values below 30 mg per day. During follow-up, microalbuminuria developed in 13 subjects (36%); the condition resolved in 2 subjects and was sustained in 4 (11%). At 6 and 12 months, the urinary albumin levels were 1812 mg and 3042 mg per day, respectively, in one subject. if the track is sealed along its entire length with thrombogenic material. 14,15 One year after final transplantation, subjects who reached the primary end point (44%) had marked improvement in glycemic control, and subjects with partial graft function (28%) had substantial clinical improvement in all measures of diabetic control, as compared with subjects with no residual islet function (28%). In addition, subjects with residual islet function had no severe hypoglycemic episodes during the first year after transplantation.
The site-to-site variation in the clinical outcome that we observed was anticipated, given the baseline experience with human-islet processing and transplantation or with sirolimus-based immunosuppressive therapy, which ranged from none to substantial at the various centers. Achievement of the primary end point was significantly affected by the previous experience at each site. Regionalization of islet-processing facilities could potentially reduce the cost and the variation in outcome and improve efficiency in future trials if islets are cultured routinely. 16, 17 A progressive loss of full islet function was observed in most subjects who became insulinindependent initially but had persistent C-peptide secretion. The transient nature of insulin independence after 1 year has been observed in single-center studies. 13, 18, 19 More detailed immunologic and histologic studies will be needed for a full understanding of the pathophysiology underlying these observations. Allograft rejection may explain the graft deterioration observed, but a lack of HLA sensitization and the gradual and incomplete loss of graft function suggest that alternative mechanisms may be operative.
Although recurrent autoimmunity may play a role, in our study, autoantibody levels did not correlate with the loss of insulin independence (data not shown). Other investigators have observed a relationship between outcome and autoantibody status in both islet and whole-pancreas transplantation with previous, less potent immunosuppressive regimens. 20-22 Most immunosuppressive drugs, including tacrolimus and sirolimus, are known to impair islet function. [23] [24] [25] Prolonged exposure to these compounds, particularly in the portal-hepatic site, may enhance diabetogenic toxic effects, 26,27 underscoring a need for alternative islet delivery sites 1,2,28 and for more potent and less diabetogenic immunosuppressive therapy, including drugs with tolerance-inducing potential. 2, [29] [30] [31] [32] Metabolic exhaustion from chronic overstimulation of a marginal islet engraftment mass may be the most plausible explanation for the discrepancy between persistent C-peptide secretion and a gradual loss of insulin independence over time, but this hypothesis remains to be proved. A similar finding has been noted previously in largeanimal models of islet autotransplantation. 32, 33 Since 2000, approximately 550 islet transplantations have been performed in more than 40 institutions. 19 Recent refinements in technique include the culture of islets, the use of oxygenated perfluorodecalin in the preparation, and "rescue" gradients (i.e., use of a more tailored osmotic gradient for a second centrifugation of the islet preparation); none of these procedures were used in our trial. Hering et al. reported high rates of insulin independence with single-donor islet infusions after modifications of the procedure for preserving the pancreas, the culture medium, and peritransplantation management, as well as alternative inductive and maintenance immunotherapies. 31, 34 In summary, our trial confirmed that islet transplantation may successfully restore longterm endogenous insulin production and glycemic stability in subjects who have type 1 diabetes mellitus with unstable baseline control. However, normal endocrine reserve is rarely achieved, and insulin independence is gradually lost in most cases over time. Persistent islet function without insulin independence provides considerable benefit, with correction of glycemic lability, as indicated by protection from hypoglycemia and improved glycated hemoglobin levels, provided the subject is able to tolerate the immunosuppressive regimen. Therefore, islet transplantation may best be considered as an evolving therapy for use in highly selected patients with severe hypoglycemia or labile type 1 diabetes mellitus, provided all other attempts to stabilize glycemic control have been exhausted. For patients seeking longterm independence from insulin, whole-pancreas transplantation appears to offer more robust metabolic reserve at the present time. 35 Clinical trials in development will focus on enhanced islet engraftment, 36-38 less toxic immunosuppressive therapy, [29] [30] [31] 34 reduced metabolic stress, reduced apoptosis, enhanced regeneration, 39 the use of living donors, 40 and the induction of immuno-logic tolerance. 2 A combination of these strategies should further improve engraftment and result in more protracted or permanent independence from insulin. Given the enormous clinical burden of diabetes, the search for alternative sources of regulated insulin-secreting cells must continue, since the current supply of islets from deceased donors cannot meet the demand.
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